

Figure S1. YAP depletion sensitized OVCAR-8 cells to AZD1775-olaparib.

YAP was depleted by siRNA, and the cells were treated with the indicated amount of AZD1775 with gemcitabine for 4 days. Viability was measured by MTT assay. The data is representative of at least three independent experiments. Significant differences between the groups were evaluated using an independent *t*-test.

* $P=0.02$, ** $P=0.0001$, *** $P=0.02$, # $P=0.0004$, ## $P=0.0006$, ### $P=0.002$.




Figure S2. Dasatinib sensitized OVCAR-8 cells to AZD1775-olaparib.

The cells were treated with the indicated amount of AZD1775 with gemcitabine in the presence or absence of 10 nM dasatinib for 4 days. The data is representative of at least three independent experiments. Significant differences between the groups were evaluated using an independent *t*-test. **P*=0.03, ***P*=0.004, ****P*=0.05, #*P*=0.01, ##*P*=0.0007, ###*P*=0.006.